Safety study of CPL500036 - low dose in schizophrenia
This study is completed in Hungary, in Poland, and in Ukraine. It is testing CPL500036 - low dose for schizophrenia.
SchizophreniaDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether CPL500036 - low dose may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive CPL500036 - low dose, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Hungary, in Poland, and in Ukraine.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: May 19, 2021
Recruitment status
Completed
Enrollment listed in the registry
189
Sponsor
Celon Pharma SA
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Hungary, Poland, Ukraine
Age range
From 18 Years to 65 Years
Official registry ID
NCT05278156
Official title
Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore Efficacy, Safety and Pharmacokinetics of CPL500036 (PDE10A Inhibitor) in Patients With an Acute Exacerbation of Schizophrenia
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Hungary · 5 sites
Department of Psychiatry and Psychotheraapy of Semmelweis University
Budapest
Site status: Not listed — confirm with the team
Semmelweis University, Faculty of Medicine, Department of Psychiatry and Psychotherapy
Budapest
Site status: Not listed — confirm with the team
Department of Psychiatry, Mental hygiene and Addictology of Petz Aladár County Teaching Hospital
Győr
Site status: Not listed — confirm with the team
Bács-Kiskun County Teaching Hospital Kalocsa Holy Cross Hospital
Kalocsa
Site status: Not listed — confirm with the team
Psychiatry Department of Tolna County Balassa Janos Hospital
Szekszárd
Site status: Not listed — confirm with the team
Poland · 4 sites
Uniwersytecki Szpital Kliniczny
Bialystok
Site status: Not listed — confirm with the team
Wojewódzki Szpital dla Nerwowo i Psychicznie Chorych
Bolesławiec
Site status: Not listed — confirm with the team
Samodzielny Publiczny Psychiatryczny Zakład Opieki Zdrowotnej
Choroszcz
Site status: Not listed — confirm with the team
Wojewódzki Szpital dla Psychicznie i Nerwowo Chorych
Gmina Świecie
Site status: Not listed — confirm with the team
Ukraine · 7 sites
Ivano-Frankivsk National Medical University, Department of Psychiatry, Narcology and Medical Psychology
Ivano-Frankivsk
Site status: Not listed — confirm with the team
Communal non-profit enterprise "Clinical Hospital "PSYCHIATRY"" of the executive body of the Kyiv City Council (Kyiv City State Administration), Center for Primary Psychotic Episode and Modern Treatment Methods.
Kyiv
Site status: Not listed — confirm with the team
Communal non-commercial enterprise of the Kyiv Regional Council "Regional Psychiatric-Narcological Medical Association", women's department No. 2, men's department No. 10.
Kyiv
Site status: Not listed — confirm with the team
Communal non-commercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Psychoneurological Dispensary",
Lviv
Site status: Not listed — confirm with the team
Communal non- commercial enterprise of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital",
Lviv
Site status: Not listed — confirm with the team
Ternopil National Medical University named after I.Y. Gorbachevskiy of the Ministry of Health of Ukraine, Department of Psychiatry, Narcology and Medical Psychology
Ternopil
Site status: Not listed — confirm with the team
Vinnytsia National Medical University named after M.I. Pirogov, Department of Psychiatry, Narcology and Psychotherapy with a course of postgraduate education
Vinnytsia
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT05278156. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving CPL500036 - low dose, CPL500036 - high dose, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Celon Pharma SA, which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
